Comparing of Theravance Biopharma Inc. (TBPH) and Aptorum Group Limited (NASDAQ:APM)

Theravance Biopharma Inc. (NASDAQ:TBPH) and Aptorum Group Limited (NASDAQ:APM), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Theravance Biopharma Inc. 57.39M 15.60 223.02M -4.10 0.00
Aptorum Group Limited N/A 1694.14 14.83M -0.53 0.00

Demonstrates Theravance Biopharma Inc. and Aptorum Group Limited earnings per share, gross revenue and valuation.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Theravance Biopharma Inc. -388.60% 0% -55.1%
Aptorum Group Limited 0.00% 0% 0%


The Current Ratio and a Quick Ratio of Theravance Biopharma Inc. are 5.4 and 5.4. Competitively, Aptorum Group Limited has 2.4 and 2.4 for Current and Quick Ratio. Theravance Biopharma Inc.’s better ability to pay short and long-term obligations than Aptorum Group Limited.

Analyst Recommendations

The table shown features the ratings and recommendations for Theravance Biopharma Inc. and Aptorum Group Limited.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Theravance Biopharma Inc. 0 0 2 3.00
Aptorum Group Limited 0 0 1 3.00

Theravance Biopharma Inc.’s average target price is $47.5, while its potential upside is 197.81%. Competitively the average target price of Aptorum Group Limited is $22, which is potential -1.87% downside. Based on the analysts view we can conclude, Theravance Biopharma Inc. is looking more favorable than Aptorum Group Limited.

Institutional and Insider Ownership

Roughly 86.4% of Theravance Biopharma Inc. shares are owned by institutional investors while 0.02% of Aptorum Group Limited are owned by institutional investors. Theravance Biopharma Inc.’s share owned by insiders are 6.5%. Insiders Competitively, owned 29.39% of Aptorum Group Limited shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Theravance Biopharma Inc. -4.52% -9.62% -22.32% -18.13% -17.2% -17.43%
Aptorum Group Limited 3.87% 65.49% 46.93% 0% 0% 44.99%

For the past year Theravance Biopharma Inc. had bearish trend while Aptorum Group Limited had bullish trend.


On 6 of the 9 factors Aptorum Group Limited beats Theravance Biopharma Inc.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The companyÂ’s product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.